San Francisco, Calif., January 21, 2014 – CollabRx, Inc. (NASDAQ: CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, announces that Gavin J. Gordon, MBA, PhD, Vice President of Business Development & Strategic Alliances, will present in Track 2 (Big Data: Storage and Management) at the Personalized Medicine World Conference (PMWC) at 2 PM (PST) on January 28, 2014. The PMWC will be held January 26-28 at the Computer History Museum, 1401 N. Shoreline Blvd, Mountain View, California. The PMWC will include presentations and panel discussions from over 100 industry leaders from around the world.
The title of Dr. Gordon’s presentation is “Clinical Genetic Sequencing in Oncology: Interpretation & Reporting.” In his presentation, Dr. Gordon will summarize the current state of next-generation sequencing (NGS) in oncology. While NGS is increasingly being applied to diagnose and inform treatment planning in oncology, the explosion of such data is expected to outpace the ability of practicing physicians to stay current on the clinical impact of the data. As a result, laboratories that provide such services are increasingly adopting the position of selling “reports”, or knowledge, and not simply test results. This paradigm shift requires competencies and capabilities not traditionally found in the laboratory environment. Dr. Gordon will summarize how data analytics companies such as CollabRx can overcome these issues and advance the field of clinical genetic sequencing in oncology.
CollabRx, Inc. (NASDAQ: CLRX) is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.
About PMWC International
PMWC International is dedicated to transforming healthcare through the global adoption of personalized medicine. The successful development and implementation of molecularly targeted therapies and companion diagnostics requires concerted leadership from multiple sectors including business, government, healthcare-delivery, research and technology. PMWC International provides a platform to foster collaboration among these key stakeholders and catalyze change. Launched by Silicon Valley investors and entrepreneurs in 2009, PMWC International has held several conferences in the U.S. and abroad to forge connections and drive innovation. More information may be obtained at http://2014sv.pmwcintl.com/.
Gavin J. Gordon, MBA, PhD
Vice President, Business Development & Strategic Alliances